Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sulfasalazine

FDA-approved product (tablet, oral), marketed as Azulfidine, Azulfidine En-Tabs, S.a.s.-500 and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sulfasalazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Juvenile idiopathic arthritis
  • Rheumatoid arthritis
  • Ulcerative colitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aminosalicylic acid and similar agents
FDA pharmacologic class
Aminosalicylate FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sulfasalazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sulfasalazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Effect of Nicorandil on Rheumatoid Arthritis Patients

    NCT07730723 · start 2026-09-06

    Registered record
    Registry ID
    NCT07730723
    Conditions
    Rheumatoid Arthritis (RA)
    Interventions
    Nicorandil Oral Tablet; Placebo; conventional synthetic antirheumatic drugs (cDMARDs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-09-06
    Completion
    2027-07
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis (RA)
    InterventionNicorandil Oral Tablet; Placebo; conventional synthetic antirheumatic drugs (cDMARDs)
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Study of ECC4703 With Sulfasalazine and Pitavastatin

    NCT07726368 · start 2026-08-07

    Registered record
    Registry ID
    NCT07726368
    Conditions
    Non-alcoholic Fatty Liver Disease (NAFLD); Dyslipidaemia
    Interventions
    ECC4703; Sulfasalazine; Pitavastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-08-07
    Completion
    2026-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-alcoholic Fatty Liver Disease (NAFLD); Dyslipidaemia
    InterventionECC4703; Sulfasalazine; Pitavastatin
    PhasePhase 1
    Registry statusRecruiting

  • Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

    NCT07138898 · start 2025-12-12

    Registered record
    Registry ID
    NCT07138898
    Conditions
    Rheumatic Disease
    Interventions
    Methotrexate; Sulfasalazine; Hydroxychloroquine; Leflunomide; Azathioprine; Mycophenolate; Cyclosporine; Tacrolimus; Etanercept; Adalimumab; Golimumab; Certolizumab; Infliximab; Rituximab; Belimumab; Tocilizumab; Anakinra; Canakinumab; Abatacept; Secukinumab; Ixekizumab; Bimekizumab; Ustekinumab; Guselkumab; Risankizumab; Tofacitinib; Upadacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-12
    Completion
    2028-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatic Disease
    InterventionMethotrexate; Sulfasalazine; Hydroxychloroquine; Leflunomide +23 more
    PhasePhase 2
    Registry statusRecruiting

  • Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators

    NCT07280741 · start 2025-12-02

    Registered record
    Registry ID
    NCT07280741
    Conditions
    Autoimmune Rheumatic Diseases
    Interventions
    Recombinant Zoster Vaccine (RZV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-12-02
    Completion
    2028-07-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutoimmune Rheumatic Diseases
    InterventionRecombinant Zoster Vaccine (RZV)
    PhasePhase 4
    Registry statusRecruiting

  • MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

    NCT06557330 · start 2025-06

    Registered record
    Registry ID
    NCT06557330
    Conditions
    Lymphoma; Indolent Non-hodgkin Lymphoma
    Interventions
    Bendamustine; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-06
    Completion
    2028-03-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Indolent Non-hodgkin Lymphoma
    InterventionBendamustine; Rituximab
    PhasePhase 2
    Registry statusNot yet recruiting

  • L-carnitine Supplementation in Rheumatoid Arthritis Patients

    NCT06753565 · start 2024-12-31

    Registered record
    Registry ID
    NCT06753565
    Conditions
    Rheumatoid Arthritis (RA)
    Interventions
    Carnitine; Disease-modifying anti-rheumatic drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-12-31
    Completion
    2025-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis (RA)
    InterventionCarnitine; Disease-modifying anti-rheumatic drugs
    PhasePhase 2
    Registry statusRecruiting

  • A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus

    NCT06360068 · start 2024-05-06

    Registered record
    Registry ID
    NCT06360068
    Conditions
    Systemic Lupus Erythematosus
    Interventions
    Sulfasalazine Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-05-06
    Completion
    2025-05-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus
    InterventionSulfasalazine Tablets
    PhasePhase 2
    Registry statusUnknown

  • Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.

    NCT06293378 · start 2024-02-01

    Registered record
    Registry ID
    NCT06293378
    Conditions
    Cirrhosis, Liver; Fibrosis, Liver
    Interventions
    Sulfasalazine enteric-coated tablets; Sulfasalazine enteric-coated tablets; Sulfasalazine enteric-coated tablets; Sulfasalazine enteric-coated tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-02-01
    Completion
    2028-10-10
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver; Fibrosis, Liver
    InterventionSulfasalazine enteric-coated tablets; Sulfasalazine enteric-coated tablets; Sulfasalazine enteric-coated tablets; Sulfasalazine enteric-coated tablets
    PhaseNot applicable
    Registry statusRecruiting

  • Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

    NCT05580861 · start 2023-05-17

    Registered record
    Registry ID
    NCT05580861
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Sulfasalazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-05-17
    Completion
    2026-12
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionSulfasalazine
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Topical Sulfasalazine and Oral Lichen Planus

    NCT06060301 · start 2023-03-01

    Registered record
    Registry ID
    NCT06060301
    Conditions
    Oral Lichen Planus; Topical Sulfasalazine; Corticosteroids
    Interventions
    sulfasalazine 500 MG; corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-03-01
    Completion
    2024-10-20
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Lichen Planus; Topical Sulfasalazine; Corticosteroids
    Interventionsulfasalazine 500 MG; corticosteroids
    PhasePhase 3
    Registry statusUnknown

  • The Effect of Cilostazol on Rheumatoid Arthritis Patients

    NCT05671497 · start 2022-11-01

    Registered record
    Registry ID
    NCT05671497
    Conditions
    Rheumatoid Arthritis
    Interventions
    Cilostazol 100 MG; conventional synthetic antirheumatic drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2022-11-01
    Completion
    2024-10-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionCilostazol 100 MG; conventional synthetic antirheumatic drugs
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Evaluation of the CapScan Device to Measure the Metabolism of Sulfasalazine

    NCT05749068 · start 2022-09-01

    Registered record
    Registry ID
    NCT05749068
    Conditions
    Healthy
    Interventions
    CapScan intestinal sampling device
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-09-01
    Completion
    2022-10-30
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCapScan intestinal sampling device
    PhaseNot applicable
    Registry statusCompleted

  • Montelukast Use in Rheumatoid Arthritis

    NCT05447520 · start 2021-12-15

    Registered record
    Registry ID
    NCT05447520
    Conditions
    Rheumatoid Arthritis
    Interventions
    Montelukast; Placebo; Conventional DMARDs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-12-15
    Completion
    2022-12-30
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionMontelukast; Placebo; Conventional DMARDs
    PhasePhase 2
    Registry statusCompleted

  • The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis

    NCT04927000 · start 2021-05-31

    Registered record
    Registry ID
    NCT04927000
    Conditions
    Rheumatoid Arthritis
    Interventions
    Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-05-31
    Completion
    2023-12-30
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionTofacitinib
    PhasePhase 4
    Registry statusUnknown

  • Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients

    NCT03847311 · start 2021-05-03

    Registered record
    Registry ID
    NCT03847311
    Conditions
    Breast Cancer; Chronic Pain Due to Malignancy (Finding)
    Interventions
    Sulfasalazine; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-05-03
    Completion
    2023-10-09
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Chronic Pain Due to Malignancy (Finding)
    InterventionSulfasalazine; Placebos
    PhasePhase 2
    Registry statusCompleted